NEW YORK -- Dalton Investments, a U.S.-based activist investor known for its outspoken positions, plans to release a letter criticizing the steps taken by Japan's Aska Pharmaceutical and Bunka Shutter to fend off would-be takeovers.
Equities
Dalton blasts Japan's Aska Pharma, Bunka Shutter for takeover defenses
Activist US fund criticizes companies for resisting management buyouts
Dalton Investments founding partner and Chief Investment Officer James B. Rosenwald. The firm is criticizing new company policies, claiming they prevent the U.S. fund from "freely trading in the open market." (Nikkei montage/Source photos by Nikkei)
Read Next
Latest on Equities
